Global Markets Direct’s, ‘Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 12 Receptor (IL12R) targeted pipeline therapeutics.
The report provides comprehensive information on the Interleukin 12 Receptor (IL12R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation.
- The report provides a snapshot of the global therapeutic landscape for Interleukin 12 Receptor (IL12R) - The report reviews Interleukin 12 Receptor (IL12R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 12 Receptor (IL12R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 12 Receptor (IL12R) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 12 Receptor (IL12R) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 12 Receptor (IL12R) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
Report Synopsis Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies’ commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences and Roche Holdings AG. The global enzymes market is expected to decline from $7.98 billion in 2019 to $7.81 billion in 2020 at a compound annual growth rate...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals. The global interleukin inhibitors market is expected to decline from $18.22 billion in 2019 to $17.93 billion in 2020 at a compound annual growth...
Insulin Like Growth Factor I - Pipeline Review, H2 2020
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived...
The global oxidative stress assay market grew at a CAGR of around 8% during 2014-2019. Oxidative stress is a health condition wherein excessive production of oxygen-derived free radicals within a cell or organism overwhelms the intrinsic antioxidant defenses. It causes oxidative damage to proteins, lipids and nucleic...
The global CDMO market is estimated to reach US$241.3 billion in 2024, growing at a CAGR of 9.80% for the period spanning from 2020 to 2024. The factors such as increasing per capita disposable income, increasing global healthcare expenditure, rising aging population, increasing R&D spending, growing number of new drugs, rise in investments...
The market for cell culture is driven by factors such as rising demand for vaccines, artificial organs and biopharmaceuticals, and growing focus on personalized medicine. Immunization is the most valuable and cost-effective intervention that delivers better health as well as social and economic benefits. Annually, around 2 to 3 million...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.